{"filing":{"accession_number":"0001140361-26-032946","cik":"0001133416","ticker":"GALT","company_name":"GALECTIN THERAPEUTICS INC","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"ef20080011_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126032946/ef20080011_8k.htm"},"events":[{"id":27738,"run_id":25313,"accession_number":"0001140361-26-032946","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a classic Item 2.02 earnings release. Galectin Therapeutics issued a press release on August 14, 2026 announcing financial results for the six months ended June 30, 2026, including condensed consolidated statements of operations and balance sheet data. The filing explicitly states the company \"issued a press release announcing its results of operations and financial condition\" and incorporates the press release by reference as Exhibit 99.1, which contains detailed quarterly financial highlights, net loss figures, and cash position disclosures typical of earnings announcements.","company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29398,"accession_number":"0001140361-26-032946","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic Item 2.02 earnings release. Galectin Therapeutics issued a press release on August 14, 2026 announcing financial results for the six months ended June 30, 2026, including condensed consolidated statements of operations and balance sheet data. The filing explicitly states the company \"issued a press release announcing its results of operations and financial condition\" and incorporates the press release by reference as Exhibit 99.1, which contains detailed quarterly financial highlights, net loss figures, and cash position disclosures typical of earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:56:37.623483+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29398,"accession_number":"0001140361-26-032946","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic Item 2.02 earnings release. Galectin Therapeutics issued a press release on August 14, 2026 announcing financial results for the six months ended June 30, 2026, including condensed consolidated statements of operations and balance sheet data. The filing explicitly states the company \"issued a press release announcing its results of operations and financial condition\" and incorporates the press release by reference as Exhibit 99.1, which contains detailed quarterly financial highlights, net loss figures, and cash position disclosures typical of earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:56:37.623483+00:00","company_name":"GALECTIN THERAPEUTICS INC","ticker":"GALT","filing_date":"2026-08-14"}]}